SARS-CoV-2 Beta Variant S recombinant monoclonal antibody

Specificity:
Reacts with RBD domain of spike protein of SARS-CoV-2, including South Africa variant (B.1.351) and UK variant (B.1.1.7).

Preparation Method:
This antibody is a CHO expressed recombinant antibody. It has the characteristic human Fc domain.

Recommend Usage:
ELISA
Neutralization Assay
The optimal working dilution should be determined by the end user.

Storage Instruction:
Store at 4°C is stable for 6 months from the date of shipment. For long term storage, store at -20°C.
Aliquot to avoid repeated freezing and thawing.

Note:
Result Data
Pseudoviral particle (PP) infection assay challenged by SARS-CoV-2 Variant B.1.351 S recombinant monoclonal antibody (Cat # RAB01067).
HEK293-ACE2 cells infected with SARS-CoV-2 pseudoviral particles under various amounts of SARS-CoV-2 Variant B.1.351 S recombinant monoclonal antibody (Cat # RAB01067), with IC50 of 42.8 ng/mL (SARS-CoV-2 Pseudoviral Particles, D614G) and 45 ng/mL (SARS-CoV-2 Pseudoviral Particles, South Africa Variant).

Enzyme-linked Immunoabsorbent Assay
Titration curves of SARS-CoV-2 Variant B.1.351 S recombinant monoclonal antibody (Cat # RAB01067). 96-well corning ELISA plate was coated with S (SARS-CoV-2 Variant B.1.351) RBD Recombinant Protein (Cat # P6703) at a concentration of 2 ug/mL, and with a EC50 of 12.19 ng/mL.